TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07767903: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Compare the Efficacy and Safety of a Fixed Dose of SEP-363856 to Placebo in the Treatment of Adults With Generalized Anxiety D

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 384 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$8,014,480

Rescue Site Savings

+$5,280,128

Unlock Full NCT07767903 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07767903 Rescue Dossier →